

IMI impact on patient involvement | 7 October 2021

Speaker bio



Jan Geissler

Founder and CEO, Patvocates GmbH

Jan Geissler is founder and CEO of [Patvocates](#), a think tank, consultancy and social enterprise in patient advocacy, health policy and patient engagement in research. From 2012-2017, he has been the Director of the '[European Patients Academy](#)' (EUPATI), which has developed patient education about medicines development processes. He also manages the [German EUPATI platform](#). Jan is also work package leader of the new IMI2-funded [EU project HARMONY](#) on big data for better outcomes in hematology.

After his university diploma in Business studies in the UK and Germany in 1999, Jan held various management positions in telecommunications, R&D and media think tanks before he focused his professional life on patient advocacy in 2008. Being a leukemia patient since 2001, Jan co-founded [LeukaNET/Leukaemie-Online.de](#) in 2002, the [European Cancer Patient Coalition](#) in 2003, the [CML Advocates Network](#) in 2007, the [Leukemia Patient Advocates Foundation](#) in 2011, the Workgroup of European Cancer Patient Advocacy Networks ([WECAN](#)) in 2015, and the [Acute Leukemia Advocates Network](#) in 2016.

He is representing patients in various advisory boards and committees e.g. as chair of the ISPOR Patient Roundtable Europe and in committees of the [European Cancer Organisation \(ECCO\)](#), [EHA](#), [EORTC](#), [EuroBloodNet](#), [Berlin Institute of Health](#), [International CML Foundation](#), the [German National Decade Against Cancer](#) and the EU Cancer Mission Assembly. He is also member of the [Ethics Committee of the Bavarian Chamber of Physicians](#).

For more information, see patvocates.net/jangeissler
Contact: Jan Geissler – jan@patvocates.net – Twitter [@jangeissler](https://twitter.com/jangeissler)